Stockscreener 앱 받기
37.22
2.90%
-1.11
시간 외 거래:
37.22
전일 마감가:
$38.33
열려 있는:
$38.33
하루 거래량:
717.48K
Relative Volume:
1.02
시가총액:
$2.34B
수익:
-
순이익/손실:
$-230.66M
주가수익비율:
-8.9167
EPS:
-4.1742
순현금흐름:
$-148.12M
1주 성능:
-9.18%
1개월 성능:
-10.12%
6개월 성능:
+33.02%
1년 성능:
+264.90%
1일 변동 폭
$36.46
$38.90
1주일 범위
$36.46
$41.72
52주 변동 폭
$8.29
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
명칭
Kodiak Sciences Inc
전화
650-281-0850
주소
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
37.22 | 2.50B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-25 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-09-22 | 개시 | Jefferies | Buy |
| 2025-08-14 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2023-12-11 | 재개 | Goldman | Sell |
| 2023-11-17 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-24 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-15 | 개시 | CapitalOne | Overweight |
| 2022-08-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-02-11 | 개시 | Goldman | Buy |
| 2022-02-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-03-12 | 개시 | Evercore ISI | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-02-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-11-30 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-03 | 개시 | Goldman | Buy |
| 2020-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-02-06 | 개시 | SunTrust | Buy |
| 2020-01-08 | 개시 | ROTH Capital | Buy |
| 2020-01-03 | 개시 | Jefferies | Buy |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-20 | 개시 | Chardan Capital Markets | Buy |
| 2018-10-29 | 개시 | Barclays | Overweight |
| 2018-10-29 | 개시 | BofA/Merrill | Buy |
| 2018-10-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences Q2 net loss widens on higher R&D costs - TradingView
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView
Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView
Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus
Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com
Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang
Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan
Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Kodiak Sciences, Inc. Statistics – HAM:K27 - TradingView
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema - marketscreener.com
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - Sahm
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com - Investing.com India
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak completes enrollment in first KSI-101 trial cohort - Investing.com
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance
Kodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammation - Stock Titan
Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday - MarketBeat
KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Janus Henderson Group PLC Raises Stake in Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak Sciences Inc Revenue Breakdown – NASDAQ:KOD - TradingView
57,400 Shares in Kodiak Sciences Inc. $KOD Acquired by Swiss National Bank - MarketBeat
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherNet Income Trends - vinanet.vn
Kodiak Sciences, Inc. Revenue Breakdown – BMV:KOD - TradingView
Kodiak Sciences Inc (KOD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kodiak Sciences Inc 주식 (KOD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
0.00%
3.22%
자본화:
|
볼륨(24시간):